



*IFW*

Certificate of Mailing (37 C.F.R. §1.8):  
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 16th day of September 2005.

s/ *Christina M. Compelube*  
Christina M. Compelube

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:  
Stephen D. Barrett, et al.

Group Art Unit: 1626

Serial No.: 10/725,206

Examiner: Not Yet Assigned

Confirmation No.: 4492

Filed: December 1, 2003

For: MEK INHIBITING COMPOUNDS

Mail Stop: Amendment  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:


- |  |                  |
|--|------------------|
| 1. Transmittal of Information Disclosure Statement | 2 pages;         |
| 2. PTO SB0/8A                                      | 3 pages;         |
| 3. Total References Submitted                      | 30 references;   |
| 4. Return Postcard                                 | 1 postcard; and  |
| 5. Total Fee Due \$0.00                            | Deposit Account. |

Respectfully submitted,

Date: September 16, 2005

*Galina Yakovleva*  
Galina M. Yakovleva, Ph.D.  
Attorney For Applicant  
Registration No. 47,192

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-6095  
Fax: (858) 678-8233

Certificate of Mailing (37 C.F.R. § 1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 16th day of September 2005.

s/

Christina M. Compelube

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
Stephen D. Barrett, et al.

Serial No.: 10/725,206

Confirmation No.: 4492

Filed: December 1, 2003

For: MEK INHIBITING COMPOUNDS

Group Art Unit: 1626

Examiner: Not Yet Assigned

Mail Stop: Amendment  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, PTO/SB/08a, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☐ Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (waiver of 37 CFR 1.98(a)(2)(iii) pursuant to 37 CFR 1.183).
- ☒ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: September 16, 2005

Galina Yakovleva  
Galina M. Yakovleva, Ph.D.  
Attorney For Applicant  
Registration No. 47,192

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-6095  
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/725,206
Filing Date	December 1, 2003
First Named Inventor	Stephen D. Barrett
Art Unit	1626
Examiner Name	To Be Assigned
Attorney Docket Number	PC20520A

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AA	EP 1 262 176	12-04-2002	Warner-Lambert Company		
	AB	WO98/37881	09-03-1998	Warner-Lambert Company		
	AC	WO99/01421	01-14-1999	Warner-Lambert Company		
	AD	WO99/01426	01-14-1999	Warner-Lambert Company		
	AE	WO99/34792	07-15-1999	The General Hospital Corporation		
	AF	WO00/35435	06-22-2000	Warner-Lambert Company		
	AG	WO00/35436	06-22-2000	Warner-Lambert Company		
	AH	WO00/37141	06-29-2000	Warner-Lambert Company		
	AI	WO00/40235	07-13-2000	Warner-Lambert Company		
	AJ	WO00/40237	07-13-2000	Warner-Lambert Company		
	AK	WO00/41505	07-20-2000	Warner-Lambert Company		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/725,206
Filing Date	December 1, 2003
First Named Inventor	Stephen D. Barrett
Art Unit	1626
Examiner Name	To Be Assigned
Attorney Docket Number	PC20520A

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AL	WO00/41994	07-20-2000	Warner-Lambert Company		
	AM	WO00/42002	07-20-2000	Warner-Lambert Company		
	AN	WO00/42003	07-20-2000	Warner-Lambert Company		
	AO	WO00/42022	07-20-2000	Warner-Lambert Company		
	AP	WO00/42029	07-20-2000	Warner-Lambert Company		
	AQ	WO01/05390	01-25-2001	Warner-Lambert Company		
	AR	WO01/05391	01-25-2001	Warner-Lambert Company		
	AS	WO01/05392	01-25-2001	Warner-Lambert Company		
	AT	WO01/05393	01-25-2001	Warner-Lambert Company		
	AU	WO01/68619	09-20-2001	Warner-Lambert Company		
	AV	WO02/06213	01-24-2002	Warner-Lambert Company		
	AW	WO02/069960	09-12-2002	Axxima Pharmaceuticals AG		
	AX	WO02/076496	10-03-2002	Van Andel Institute		
	AY	WO02/18319	03-07-2002	Warner-Lambert Company		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.


Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/725,206
Filing Date	December 1, 2003
First Named Inventor	Stephen D. Barrett
Art Unit	1626
Examiner Name	To Be Assigned
Attorney Docket Number	PC20520A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AZ	Chemical Abstract Accession No. 1969:480862. [TIER, J. et al., "Nitrogen Atom Conjugation In Polynuclear Uncondensed Aromatic Systems," <i>Bulletin de la Societe Chimique de France</i> , 1969, 7, 2342-2355.]	
	BA	DABROWSKI, J. et al., "Symmetrically Bifurcate Hydrogen Bonding-III <sup>1</sup> (sym-o,o' Diacyl)-Diphenylamines," <i>Tetrahedron</i> , 1973, 29, 2257-2260.	
	BB	DOPPLER, T. et al., "Photolysis Of 3-Methyl-2,1-Benzisoxazole (3-Methylanthranil) And 2-Azido-Acetophenone In The Presence Of Sulfuric Acid And Benzene Derivatives," <i>Helvetica Chimica Acta</i> , 1979, 62:33, 304-313.	
	BC	PCT International Search Report for PCT/IB03/05787.	
	BD	SEBOLT-LEOPOLD, J., "Blockade Of The MAP Kinase Pathway Suppresses Growth Of Colon Tumors In Vivo," <i>Nature Medicine</i> , 1999, 5:7, 810-816.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.